NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,037,061.60 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 32,612 shares of the business’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $774,425.40. This trade represents a 57.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, January 27th, Louise Frederika Kooij sold 39,816 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $32.62, for a total value of $1,298,797.92.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.78, for a total value of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.75, for a total transaction of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total value of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded down $0.44 during trading hours on Thursday, reaching $31.44. 329,968 shares of the company were exchanged, compared to its average volume of 715,688. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -15.34 and a beta of 0.07. The stock has a 50 day simple moving average of $35.32 and a 200 day simple moving average of $31.25. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. On average, analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on NAMS. HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a report on Monday, October 20th. They set a “buy” rating and a $52.00 target price on the stock. Royal Bank Of Canada upped their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. The Goldman Sachs Group increased their price objective on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. Citigroup boosted their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Stifel Nicolaus upped their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its position in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the last quarter. Mather Group LLC. acquired a new position in NewAmsterdam Pharma in the third quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in NewAmsterdam Pharma in the 3rd quarter worth about $30,000. Wolverine Asset Management LLC acquired a new position in NewAmsterdam Pharma in the 3rd quarter worth approximately $69,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in NewAmsterdam Pharma by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock worth $79,000 after acquiring an additional 662 shares during the period. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.